These data demonstrate that antibody blockade of CD36 and CCL2 prevents the NASH progression in Mettl3-HKO mice and further supports the theory that elevated CD36 and CCL2 contribute to NASH progression in Mettl3-HKO mice. Here, METTL3 is linked to metabolic dysfunction-associated steatohepatitis.